Diabetic Neuropathic Pain - Pipeline Review, H1 2016

  • ID: 3641068
  • Report
  • 100 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • Boehringer Ingelheim GmbH
  • Eli Lilly and Company
  • Hydra Biosciences, Inc.
  • Mertiva AB
  • Novaremed
  • MORE
Diabetic Neuropathic Pain - Pipeline Review, H1 2016

Summary

‘Diabetic Neuropathic Pain - Pipeline Review, H1 2016’, provides an overview of the Diabetic Neuropathic Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Neuropathic Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Neuropathic Pain and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diabetic Neuropathic Pain
- The report reviews pipeline therapeutics for Diabetic Neuropathic Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Diabetic Neuropathic Pain therapeutics and enlists all their major and minor projects
- The report assesses Diabetic Neuropathic Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Diabetic Neuropathic Pain

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathic Pain
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Diabetic Neuropathic Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • Boehringer Ingelheim GmbH
  • Eli Lilly and Company
  • Hydra Biosciences, Inc.
  • Mertiva AB
  • Novaremed
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Diabetic Neuropathic Pain Overview

Therapeutics Development

Pipeline Products for Diabetic Neuropathic Pain - Overview

Pipeline Products for Diabetic Neuropathic Pain - Comparative Analysis

Diabetic Neuropathic Pain - Therapeutics under Development by Companies

Diabetic Neuropathic Pain - Therapeutics under Investigation by Universities/Institutes

Diabetic Neuropathic Pain - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Diabetic Neuropathic Pain - Products under Development by Companies

Diabetic Neuropathic Pain - Products under Investigation by Universities/Institutes

Diabetic Neuropathic Pain - Companies Involved in Therapeutics Development

Astellas Pharma Inc.

BioDelivery Sciences International, Inc.

Boehringer Ingelheim GmbH

Daiichi Sankyo Company, Limited

Eli Lilly and Company

Glenmark Pharmaceuticals Ltd.

Hydra Biosciences, Inc.

Immune Pharmaceuticals Inc.

Laboratorios Del Dr. Esteve S.A.

Lohocla Research Corporation

Mertiva AB

Novaremed

PeriphaGen, Inc.

Pharmaleads

Prismic Pharmaceuticals, Inc.

Relmada Therapeutics, Inc.

Sphaera Pharma Pvt. Ltd.

Theravasc, Inc.

Diabetic Neuropathic Pain - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(amitriptyline + ketamine hydrochloride) - Drug Profile

Product Description

Mechanism of Action

R&D Progress

(diclofenac sodium + triclocarban) - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AS-1069562 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ASP-3662 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

capsaicin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

clonidine hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

duloxetine hydrochloride DR - Drug Profile

Product Description

Mechanism of Action

R&D Progress

E-52862 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

EC-5026 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

filgrastim - Drug Profile

Product Description

Mechanism of Action

R&D Progress

GERPOOI - Drug Profile

Product Description

Mechanism of Action

R&D Progress

GRC-17536 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

HC-030031 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Kindolor - Drug Profile

Product Description

Mechanism of Action

R&D Progress

mepivacaine hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

mirogabalin besylate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

NG2-GAD - Drug Profile

Product Description

Mechanism of Action

R&D Progress

NRD-135SE1 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

palmidrol - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PGN-305 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PL-37 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Agonize CB2 for Diabetic Neuropathic Pain - Drug Profile

Product Description

Mechanism of Action

R&D Progress

sodium nitrite SR - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Diabetic Neuropathic Pain - Recent Pipeline Updates

Diabetic Neuropathic Pain - Dormant Projects

Diabetic Neuropathic Pain - Discontinued Products

Diabetic Neuropathic Pain - Product Development Milestones

Featured News & Press Releases

Jan 06, 2016: Hydra Biosciences to Present at the 8th Annual Biotech Showcase Conference in San Francisco on Jan. 11

Sep 28, 2015: Pharmaleads Announces the Opening of French Sites in Its International Phase IIa Clinical Study of PL37

Apr 22, 2015: Pharmaleads Announces the Inclusion of the First Patient in Phase IIa Study of Oral PL37 for Pain in Diabetic Neuropathy

Mar 30, 2015: BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development

Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin

Dec 08, 2014: BioDelivery Sciences Announces Completion of Randomization in Phase 3 Trial of Clonidine Topical Gel for the Treatment of Painful Diabetic Neuropathy

Aug 06, 2014: BioDelivery Sciences Provides Update on Ongoing Phase 3 Pivotal Trial for Clonidine Topical Gel for Painful Diabetic Neuropathy

Oct 30, 2012: Drug Offers New Pain Management Therapy For Diabetics, Study Finds

Jun 04, 2012: EpiCept Receives Scientific Advice From EMA For AmiKet CIPN Program

Feb 22, 2012: Shionogi And Lilly Japan Announce Approval Of Additional Indication For Cymbalta In Japan

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Diabetic Neuropathic Pain, H1 2016

Number of Products under Development for Diabetic Neuropathic Pain - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Diabetic Neuropathic Pain - Pipeline by Astellas Pharma Inc., H1 2016

Diabetic Neuropathic Pain - Pipeline by BioDelivery Sciences International, Inc., H1 2016

Diabetic Neuropathic Pain - Pipeline by Boehringer Ingelheim GmbH, H1 2016

Diabetic Neuropathic Pain - Pipeline by Daiichi Sankyo Company, Limited, H1 2016

Diabetic Neuropathic Pain - Pipeline by Eli Lilly and Company, H1 2016

Diabetic Neuropathic Pain - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2016

Diabetic Neuropathic Pain - Pipeline by Hydra Biosciences, Inc., H1 2016

Diabetic Neuropathic Pain - Pipeline by Immune Pharmaceuticals Inc., H1 2016

Diabetic Neuropathic Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H1 2016

Diabetic Neuropathic Pain - Pipeline by Lohocla Research Corporation, H1 2016

Diabetic Neuropathic Pain - Pipeline by Mertiva AB, H1 2016

Diabetic Neuropathic Pain - Pipeline by Novaremed, H1 2016

Diabetic Neuropathic Pain - Pipeline by PeriphaGen, Inc., H1 2016

Diabetic Neuropathic Pain - Pipeline by Pharmaleads , H1 2016

Diabetic Neuropathic Pain - Pipeline by Prismic Pharmaceuticals, Inc., H1 2016

Diabetic Neuropathic Pain - Pipeline by Relmada Therapeutics, Inc., H1 2016

Diabetic Neuropathic Pain - Pipeline by Sphaera Pharma Pvt. Ltd., H1 2016

Diabetic Neuropathic Pain - Pipeline by Theravasc, Inc., H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Diabetic Neuropathic Pain Therapeutics - Recent Pipeline Updates, H1 2016

Diabetic Neuropathic Pain - Dormant Projects, H1 2016

Diabetic Neuropathic Pain - Dormant Projects (Contd..1), H1 2016

Diabetic Neuropathic Pain - Dormant Projects (Contd..2), H1 2016

Diabetic Neuropathic Pain - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Diabetic Neuropathic Pain, H1 2016

Number of Products under Development for Diabetic Neuropathic Pain - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Astellas Pharma Inc.
BioDelivery Sciences International, Inc.
Boehringer Ingelheim GmbH
Daiichi Sankyo Company, Limited
Eli Lilly and Company
Glenmark Pharmaceuticals Ltd.
Hydra Biosciences, Inc.
Immune Pharmaceuticals Inc.
Laboratorios Del Dr. Esteve S.A.
Lohocla Research Corporation
Mertiva AB
Novaremed
PeriphaGen, Inc.
Pharmaleads
Prismic Pharmaceuticals, Inc.
Relmada Therapeutics, Inc.
Sphaera Pharma Pvt. Ltd.
Theravasc, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll